{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:00:33Z","timestamp":1781218833816,"version":"3.54.1"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"DOI":"10.1055\/a-2729-3885","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:52:56Z","timestamp":1781218376000},"source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Glaukomtherapie"],"prefix":"10.1055","author":[{"given":"Charlotte","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial","volume":"120","author":"A Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"MA Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma","volume":"126","author":"W Alward","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"09","key":"ref4","doi-asserted-by":"publisher","first-page":"CD004399","DOI":"10.1002\/14651858.CD004399.pub3","article-title":"Medical versus surgical interventions for open angle glaucoma","author":"J Burr","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315613","article-title":"Selective laser trabeculoplasty versus medication for open-angle glaucoma: Systematic review and meta-analysis of randomised clinical trials","author":"SC Chi","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","article-title":"European Glaucoma Society \u2013 Terminology and guidelines for glaucoma. 6th ed","volume":"109","author":"M Pazos","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma","volume":"123","author":"T Li","year":"2016","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial","volume":"385","author":"DF Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/IJG.0000000000002371","article-title":"Preservative-free Bimatoprost 0.01% ophthalmic gel for glaucoma therapy: A phase III randomized controlled trial","volume":"33","author":"FJ Mu\u00f1oz-Negrete","year":"2024","journal-title":"J Glaucoma"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/IOP.0b013e31817d81df","article-title":"Periorbital changes associated with topical bimatoprost","volume":"24","author":"T Filippopoulos","year":"2008","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181550","article-title":"Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy","volume":"12","author":"T Miki","year":"2017","journal-title":"PloS One"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ogla.2024.10.010","article-title":"Incidence of uveitis following initiation of prostaglandin analogs versus other glaucoma medications: A study from the sight outcomes research collaborative repository","volume":"8","author":"MZ Chauhan","year":"2025","journal-title":"Ophthalmol Glaucoma"},{"issue":"06","key":"ref13","doi-asserted-by":"publisher","first-page":"CD013817","DOI":"10.1002\/14651858.CD013817.pub2","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","author":"J Clement Freiberg","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"AP Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315623","article-title":"Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: A systematic review and meta-analysis","author":"A Hedengran","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02338.x","article-title":"Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: A randomized clinical trial","volume":"90","author":"AM Stevens","year":"2012","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1136\/bjophthalmol-2011-300012","article-title":"Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines","volume":"95","author":"DA Ammar","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ogla.2019.10.002","article-title":"Evaluation of generic versus original prostaglandin analogues in the treatment of glaucoma","volume":"3","author":"AT Steensberg","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"issue":"04","key":"ref19","doi-asserted-by":"publisher","first-page":"CD006132","DOI":"10.1002\/14651858.CD006132.pub3","article-title":"Interventions for improving adherence to ocular hypotensive therapy","author":"H Waterman","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"598.e1","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"BL Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajo.2024.02.010","article-title":"Omidenepag Isopropyl versus Timolol in patients with glaucoma or ocular hypertension: Two randomized phase 3 trials (SPECTRUM 4 and 3)","volume":"263","author":"J Bacharach","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ogla.2025.02.004","article-title":"Sepetaprost 0.002% noninferiority vs. Timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension","volume":"8","author":"DL Wirta","year":"2025","journal-title":"Ophthalmol Glaucoma"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/bph.14328","article-title":"Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma","volume":"176","author":"F Impagnatiello","year":"2019","journal-title":"Br J Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","article-title":"A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The VOYAGER study","volume":"99","author":"RN Weinreb","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40123-024-00898-y","article-title":"Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial","volume":"13","author":"SR Sarkisian","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40265-025-02154-4","article-title":"Safety and longevity of intraocular pressure control after bimatoprost implant administration: Interim analysis of a phase 3b clinical trial (TRITON)","volume":"85","author":"SM Silverstein","year":"2025","journal-title":"Drugs"},{"issue":"08","key":"ref27","doi-asserted-by":"publisher","first-page":"CD003919","DOI":"10.1002\/14651858.CD003919.pub3","article-title":"Laser trabeculoplasty for open-angle glaucoma and ocular hypertension","author":"CR Rolim-de-Moura","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.ophtha.2019.04.012","article-title":"Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension","volume":"126","author":"A Garg","year":"2019","journal-title":"Ophthalmology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): A multicentre randomised controlled trial","volume":"393","author":"G Gazzard","year":"2019","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in glaucoma and ocular hypertension (LiGHT) trial","volume":"130","author":"G Gazzard","year":"2023","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ophtha.2025.05.004","article-title":"Randomized noninferiority trial of direct selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension: GLAUrious study","volume":"132","author":"G Gazzard","year":"2025","journal-title":"Ophthalmology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ophtha.2024.01.007","article-title":"Evaluating primary treatment for people with advanced glaucoma","volume":"131","author":"AJ King","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2729-3885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:52:56Z","timestamp":1781218376000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2729-3885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1055\/a-2729-3885","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}